WISE S.p.A., the Italian implantable-electrode company, has closed an oversubscribed Series D round of €30 million (about $34.8 million at current rates) with Italian biomedical foundation ENEA Tech and Biomedical entering the round as a new strategic investor. The round closed on 17 June 2026 and was announced through an AFP-distributed company release and corroborated by MassDevice, Medical Device Network, and other specialist medtech trade press the same day.
The proceeds will fund development and clinical adoption of WISE’s Heron lead, a spinal cord stimulation (SCS) electrode designed for percutaneous implantation. WISE describes Heron as the first SCS lead engineered to combine the directional, targeted stimulation profile of surgical paddle leads with the lower procedural burden of conventional cylindrical leads. SCS is used for chronic pain indications, particularly failed-back-surgery syndrome and complex regional pain syndrome, and sits among the larger neuromodulation indication areas by current global revenue.
What the company does
WISE manufactures implantable electrodes for three categories of clinical application: neuromonitoring, neuromodulation, and brain-computer interface. The core technology, which the company brands as “Supersonic Technology,” produces stretchable electronic circuits inside ultra-thin elastomeric foils. Compared to conventional rigid metal electrodes, the WISE devices conform to neural tissue with less mechanical mismatch, which the company says reduces tissue trauma and improves long-term signal quality. The same fabrication approach underlies Heron and the company’s BCI-facing electrode lines.
Why the round matters for the bioelectronic-medicine cohort
ENEA Tech and Biomedical, the new strategic investor on the round, is an Italian state-affiliated biomedical innovation foundation that channels public-sector capital into device companies positioned for clinical translation. Its entry to the WISE cap table signals a European institutional bet on percutaneous, directional SCS as a near-term commercial route to scale, distinct from the high-channel-count cortical interfaces dominating BCI press coverage. The SCS market is dominated by Medtronic, Abbott, Boston Scientific, and Nevro, with smaller specialists including Saluda Medical and Nalu Medical competing on lead design and stimulation patterns. WISE’s positioning is on the lead-design side rather than the stimulator generator side.
What the proceeds will fund
Per the company’s statement, the funds will advance clinical adoption of Heron and continue platform development of the underlying Supersonic Technology. WISE has not disclosed regulatory milestones for the round, named US or European launch territories beyond what’s already in market, or guided to a Series E timeline. The company did identify “expanded clinical adoption” of the Heron lead as the principal allocation, which suggests commercial-execution capital rather than research-stage runway.
Context: the wider bioelectronic-medicine funding cycle
The WISE round lands in a period that has seen ONWARD Medical raise €40.6 million in April 2026 and a wider bioelectronic-medicine funding cycle reopen across European and US specialists. Funding capacity is now coming online across the sector, with capital concentrating in companies positioned at the commercial inflection between device technology and reimbursable clinical use. WISE’s Series D fits that pattern: late-stage capital deployed against a near-term clinical translation programme rather than upstream platform research.
What to watch
The Heron lead’s clinical adoption rate over the next 12 to 18 months is the load-bearing variable for the round’s investment thesis. WISE has not disclosed which payer markets or reimbursement codes Heron will target first. The other question is whether ENEA Tech and Biomedical’s institutional commitment opens additional European-market non-dilutive capital for WISE in 2027, or whether this round positions the company toward US commercial expansion through partnership or M&A.
Sources
- WISE Closes Oversubscribed Series D Financing Round of €30 Million, Welcoming ENEA Tech and Biomedical as Strategic New Investor (AFP wire, 17 June 2026)
- WISE closes $34.8M Series D to support neurostim tech (MassDevice, 17 June 2026)
- Italy’s WISE raises $34.8m in Series D to advance spinal cord stimulator development (Medical Device Network)
- BastillePost coverage (republishing AFP)